Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Quizartinib: A New Hope in Acute Myeloid Leukemia, an Applied Comprehensive Review Publisher Pubmed



Moallem FE1 ; Gholami Chahkand MS1 ; Dadkhah PA2 ; Azarm E2 ; Shahrokhi M3 ; Deyhimi MS2 ; Karimi MA4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran
  2. 2. School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
  4. 4. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Future Oncology Published:2024


Abstract

Acute myeloid leukemia (AML) is caused by a defective precursor leading to malignant clonal expansion, often with FMS-like tyrosine kinase-3 receptor (FLT3) mutations, particularly internal tandem duplication (ITD), which has a poor prognosis. Quizartinib, a second-generation FLT3 inhibitor, has FDA approval for relapsed/refractory AML with FLT3/ITD mutation. It has shown promise in clinical studies since 2013 due to its excellent oral absorption and potent activity on FLT3. This review explores Quizartinib's mechanism of action, efficacy in monotherapy or combination with chemotherapy, drug interactions, adverse events, resistance mechanisms and future research directions. © 2024 Informa UK Limited, trading as Taylor & Francis Group.
Related Docs
View other Related Docs
1. Development of Epigenetic Modifiers With Therapeutic Potential in Fms-Related Tyrosine Kinase 3/Internal Tandem Duplication (Flt3/Itd) Acute Myeloid Leukemia and Other Blood Malignancies, ACS Pharmacology and Translational Science (2024)
2. The Importance of Personalized Medicine in Chronic Myeloid Leukemia Management: A Narrative Review, Egyptian Journal of Medical Human Genetics (2023)
3. Arms-Pcr Versus As-Pcr to Evaluate Jak2v617f Mutation in Patients With Non-Cml Myeloproliferative Neoplasms, Tehran University Medical Journal (2010)
4. Jak2-V617f Mutation and Philadelphia Positive Chronic Myeloid Leukemia, International Journal of Hematology-Oncology and Stem Cell Research (2009)
5. The Correlation Between Flt3-Itd Mutation in Dendritic Cells With Tim-3 Expression in Acute Myeloid Leukemia, Blood Science (2021)
6. Tim-3 in Leukemia; Immune Response and Beyond, Frontiers in Oncology (2021)
7. Incidence and Clinical Importance of Bcr-Abl1 Mutations in Iranian Patients With Chronic Myeloid Leukemia on Imatinib, Journal of Human Genetics (2015)
8. Comparisions of Arms-Pcr and As-Pcr for the Evaluation of Jak2v617f Mutation in Patients With Non-Cml Myeloproliferative Neoplasms, International Journal of Hematology-Oncology and Stem Cell Research (2010)
Experts (# of related papers)
Mazdak Ganjalikhani Hakemi (3)
Rasoul Salehi (1)
Other Related Docs
9. Potential Role of Autophagy Induced by Flt3-Itd and Acid Ceramidase in Acute Myeloid Leukemia Chemo-Resistance: New Insights, Cell Communication and Signaling (2022)
10. The Correlation Between Pax5 Deletion and Patients Survival in Iranian Children With Precursor B-Cell Acute Lymphocytic Leukemia, Cellular and Molecular Biology (2017)
11. Implementation of Docking, Molecular Dynamics and Free Energy to Investigate Drug Potency of Novel Bcr-Ablt315i Inhibitors As an Alternative to Ponatinib, Computational Toxicology (2021)